SCHEMBL5760067

SCHEMBL5760067

N#CCc1ccc(NS(=O)(=O)c2ccc(Cc3ccc4oc(=O)cc(C(F)(F)F)c4c3)cc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 6/20 0.46
ALDH1A1 P00352 5/20 0.45
LMNA P02545 3/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
MAPT P10636 2/20 0.45
TSHR P16473 1/20 0.43
KDM4E B2RXH2 3/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
GLA P06280 2/20 0.41
GAA P10253 2/20 0.41
POLB P06746 2/20 0.41
ERAP1 Q9NZ08 1/20 0.41
FFAR4 Q5NUL3 1/20 0.39
AR P10275 1/20 0.39
HIF1A Q16665 1/20 0.39
TP53 P04637 1/20 0.37
HSPD1 P10809 1/20 0.37
PTPN2 P17706 1/20 0.37
PTPN1 P18031 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5759426 0.88 PKM (0.53) PKMALDH1A1MAPTKDM4EMEN1
SCHEMBL5762376 0.87 PKM (0.41) PKMALDH1A1LMNASMN1; SMN2MAPT
SCHEMBL5860039 0.87 PKM (0.43) PKMALDH1A1LMNASMN1; SMN2KDM4E
SCHEMBL5763574 0.87 HTT (0.50) PKMALDH1A1KDM4EMEN1KMT2A
SCHEMBL5760245 0.87 KMT2A (0.55) PKMALDH1A1MAPTKDM4EMEN1
SCHEMBL5760427 0.87 KDM4E (0.48) PKMALDH1A1LMNAMAPTKDM4E
SCHEMBL5761750 0.87 KDM4E (0.46) PKMALDH1A1LMNAKDM4EMEN1
SCHEMBL5860372 0.87 PKM (0.41) PKMALDH1A1LMNASMN1; SMN2MAPT
SCHEMBL5860303 0.86 PKM (0.41) PKMALDH1A1LMNASMN1; SMN2MAPT
SCHEMBL5761019 0.85 AR (0.48) PKMALDH1A1LMNASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7098340-B2 Quinoline/chromene derivatives as androgen antagonist WARNER LAMBERT COMPANY LLC (US) 2006-08-29 US claimed
EP-1633732-A1 BENZYL SULFONAMIDE DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 2006-03-15 EP claimed
US-20050137228-A1 Benzyl sulfonamide derivatives DU DANIEL Y (US) 2005-06-23 US claimed
WO-2004101544-A1 BENZYL SULFONAMIDE DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY LLC (US) 2004-11-25 WO claimed
US-7098340-B2 Quinoline/chromene derivatives as androgen antagonist WARNER LAMBERT COMPANY LLC (US) 2006-08-29 US disclosed
US-20050137228-A1 Benzyl sulfonamide derivatives DU DANIEL Y (US) 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137228-A1 Benzyl sulfonamide derivatives AR, SHBG, BRDT PKM 3273/4885ALDH1A1 1928/4885LMNA 3279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.